Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Sebastian

Showing results (71-80 of 183) with videos related to

Pageof 19
Sort By:
Therapeutic Advances in Medical Oncology|March 31, 2022
Real-world multicentre analysis of neoadjuvant immunotherapy and chemotherapy in localized or oligometastatic non-small cell lung cancer (KOMPASSneoOP)Martin Faehling, Hanno Witte, Martin Sebastian, et al.
Lung Cancer (Amsterdam, Netherlands)|September 10, 2015
Humoral immune responses of lung cancer patients against the Transmembrane Phosphatase with TEnsin homology (TPTE)Andreas Kuemmel, Petra Simon, Andrea Breitkreuz, et al.
Cancer Immunology, Immunotherapy : CII|March 16, 2012
Hodgkin's lymphoma RNA-transfected dendritic cells induce cancer/testis antigen-specific immune responsesCarolin Winkler, Daniel Sebastian Steingrube, Wolfgang Altermann, et al.
Elife|March 1, 2022
GFPT2/GFAT2 and AMDHD2 act in tandem to control the hexosamine pathwayVirginia Kroef, Sabine Ruegenberg, Moritz Horn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II studyThomas J Lynch, Igor Bondarenko, Alexander Luft, et al.
Elife|July 27, 2021
miR-1 coordinately regulates lysosomal v-ATPase and biogenesis to impact proteotoxicity and muscle function during agingIsabelle Schiffer, Birgit Gerisch, Kazuto Kawamura, et al.
The American Journal of Cardiology|September 17, 2011
Long-term predictors of mortality after percutaneous coronary intervention in the era of drug-eluting stentsWilliam McLeish Wilson, Nick Andrianopoulos, David Clark, et al.
Clinical Lung Cancer|January 22, 2013
A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancerWolfgang H W Schuette, Andreas Gröschel, Martin Sebastian, et al.
European Journal of Cancer (Oxford, England : 1990)|February 2, 2025
Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysisFabian Acker, Martin Reck, Daniel Martin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 8, 2010
The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trialMartin Sebastian, Martin Reck, Cornelius F Waller, et al.
Pageof 19

Showing results (71-80 of 183) with videos related to

Sort By:
Pageof 19
Therapeutic Advances in Medical Oncology|March 31, 2022
Real-world multicentre analysis of neoadjuvant immunotherapy and chemotherapy in localized or oligometastatic non-small cell lung cancer (KOMPASSneoOP)Martin Faehling, Hanno Witte, Martin Sebastian, et al.
Lung Cancer (Amsterdam, Netherlands)|September 10, 2015
Humoral immune responses of lung cancer patients against the Transmembrane Phosphatase with TEnsin homology (TPTE)Andreas Kuemmel, Petra Simon, Andrea Breitkreuz, et al.
Cancer Immunology, Immunotherapy : CII|March 16, 2012
Hodgkin's lymphoma RNA-transfected dendritic cells induce cancer/testis antigen-specific immune responsesCarolin Winkler, Daniel Sebastian Steingrube, Wolfgang Altermann, et al.
Elife|March 1, 2022
GFPT2/GFAT2 and AMDHD2 act in tandem to control the hexosamine pathwayVirginia Kroef, Sabine Ruegenberg, Moritz Horn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II studyThomas J Lynch, Igor Bondarenko, Alexander Luft, et al.
Elife|July 27, 2021
miR-1 coordinately regulates lysosomal v-ATPase and biogenesis to impact proteotoxicity and muscle function during agingIsabelle Schiffer, Birgit Gerisch, Kazuto Kawamura, et al.
The American Journal of Cardiology|September 17, 2011
Long-term predictors of mortality after percutaneous coronary intervention in the era of drug-eluting stentsWilliam McLeish Wilson, Nick Andrianopoulos, David Clark, et al.
Clinical Lung Cancer|January 22, 2013
A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancerWolfgang H W Schuette, Andreas Gröschel, Martin Sebastian, et al.
European Journal of Cancer (Oxford, England : 1990)|February 2, 2025
Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysisFabian Acker, Martin Reck, Daniel Martin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 8, 2010
The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trialMartin Sebastian, Martin Reck, Cornelius F Waller, et al.
Pageof 19